


UNIVERSITY OF TORONTO
LESLIE DAN FACULTY OF PHARMACY

Updated: December 12, 2022

## PAXLOVIDTM FOR A PATIENT ON A DOAC DIRECT ORAL ANTICOAGULANT

who is also at high risk of hospitalization from COVID-19 (e.g., unvaccinated, immunocompromised, or over 60 years old)




 $^{*}$ Decisions to hold, adjust, or change medications should be made on a patient-specific basis.

This document is intended for use by experienced clinicians, including prescribers and pharmacists. The information is not intended to replace sound professional judgment in individual situations, and should be used in conjunction with other reliable sources of information. Clinicians should always consider the risk/benefit profile for their individual patient, discuss these risks with the patient or caregiver before initiating therapy, and closely monitor for treatment benefit and adverse effects.







 People who take a DOAC should stay up to date with their COVID-19 vaccines, including boosters.

It can be challenging to manage drug interactions between COVID-19 treatments and DOACs. Vaccination can reduce the risk of needing treatment for COVID-19.

Contributors: Kelly Grindrod, BScPharm, PharmD, MSc. Claudia Bucci, BScPhm, PharmD, ACPR. Stephanie Carlin, PharmD, ACPR2. Andrea Chittle, MD, CCFP. Noah Ivers, MD, PhD, CCFP. Heather Kertland, PharmD, FCSHP. Tara Kiran, MD, MSc, CCFP, FCFP. Kori Leblanc, BScPhm, PharmD, ACPR. Catia Marzolini, PharmD, PhD. Kate Miller, MD, CCFP, FCFP. Menaka Pai, MSc, MD, FRCPC. Adrian Poon, BA. Alice Tseng, PharmD, FCSHP, AAHIVP. Kristen Watt, BScPhm, RPh. Samira Jeimy, MD, PhD, FRCPC. Reviewed by: Rosemary Killeen, BScPhm, PGCert, RPh.

Financial contribution from.

Public Health
Agency of Canada

